1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Genentech’s Subcutaneous Tecentriq Shows Non-Inferiority To I.V. Formulation

 
• By Joseph Haas

The Roche affiliate hopes to bring subcutaneous Tecentriq to market, offering patient and clinician advantages while also beating Merck’s Keytruda and Bristol’s Opdivo to the finish line

SubQ
Genentech plans to seek approval of a subcutaneous version of Tecentriq • Source: Shutterstock

Developers of the top-selling checkpoint inhibitor therapies for cancer are competing to bring the first subcutaneous formulation to market and Genentech, Inc. announced a major step in that goal on 2 August, revealing that a pivotal study testing a subcutaneous formulation of its anti-PD-L1 therapy Tecentriq (atezolizumab) versus the current intravenous formula met the primary endpoints.

The Roche Holding AG subsidiary did not provide any numerical data from the Phase Ib/III IMscin001 trial, but said its subcutaneous formulation showed non-inferior levels of drug in patients’ blood compared with I.V. Tecentriq

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from R&D

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.